20. oktoober 2007

Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine.

<strong><br /></strong>PARIS- Oct. 21 /PRNewswire / --Sanofi-aventis announced today that the Japanese Ministry ofHealth- Labor and Welfare (MHLW) has granted approval for aSupplemental New Drug Application (sNDA) for the indication of"Acute coronary syndrome (unstable angina pectoris- non-STelevation myocardial infarction) for which percutaneous coronaryintervention (PCI) is being planned" for Plavix(R)(clopidogrel).

Approximately 100-000 patients develop an acute coronarysyndrome (ACS) and elect to undergo PCI every year in Japan --where Plavix(R) is now the first drug approved in this indication--- the largest number of patients in the world outside of theUnited States. "We are pleased that the innovative therapy-Plavix(R) is now available to physicians in Japan- offering them anew treatment option with proven outcomes and safety across ACSpatients with planned PCI-" said Hanspeter Spek- ExecutiveVice-President Pharmaceutical Operation of sanofi-aventis.